Continuation and maintenance therapy of early-onset major depressive disorder

Graham J. Emslie, Taryn L. Mayes, Maryse Ruberu

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

Child and adolescent depression is a serious and often episodic disorder with a high rate of recurrence equal to or surpassing that of adult depression. Symptoms of depression are similar in child, adolescent, and adult populations. The diagnostic criteria are the same, with the possible exception that children and adolescents are more likely to present with irritability without clear sadness. Despite the similarities between adult, adolescent, and child depression, results of studies of psychosocial and pharmacologic treatments in adult depression are not necessarily applicable to the pediatric population. The treatment of depression has been divided into three phases: acute (leading to clinical response and remission of symptoms); continuation (prevention of symptom relapse); and maintenance (prevention of new episodes or recurrences). According to research of acute treatment of child and adolescent depression with pharmacotherapy, selective serotonin reuptake inhibitors (SSRIs) are considered the first-line treatment. Recent controversies have caused some concern about the use of SSRIs in children and adolescents; however, SSRIs remain the initial pharmacologic treatment of choice. Acute treatment with non-specific psychotherapy is considered an essential component in the management of depression, but has not been shown to be equally effective as pharmacotherapy or specific psychotherapies by itself. There is increasing evidence that cognitive behavior therapy and interpersonal therapy are effective for the treatment of early-onset depression. Unfortunately, severe depression, comorbid diagnoses, family discord, and increased impairment may hinder the establishment of remission; these factors have been associated with treatment resistance. Once remission of depressive symptoms is established, continuation and maintenance treatment should be considered. Only one study of continuation treatment has been completed in child and adolescent depression; the results support the use of fluoxetine as a safe and effective treatment for reducing relapse. To date, no studies have been reported on maintenance treatment with specific therapies in child and adolescent depression, but trials in adults have demonstrated the importance of continued pharmacotherapy beyond the continuation phase of the illness. Although several factors are associated with response to treatment in children and adolescents with depression, including younger age, lower severity of depressive symptoms, higher family functioning, and fewer comorbid diagnoses, few studies have consistently demonstrated predictors of relapse and recurrence.

Original languageEnglish (US)
Pages (from-to)203-217
Number of pages15
JournalPediatric Drugs
Volume7
Issue number4
DOIs
StatePublished - 2005

Fingerprint

Major Depressive Disorder
Depression
Therapeutics
Serotonin Uptake Inhibitors
Recurrence
Drug Therapy
Psychotherapy
Fluoxetine
Cognitive Therapy
Secondary Prevention
Population

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Pharmacology

Cite this

Continuation and maintenance therapy of early-onset major depressive disorder. / Emslie, Graham J.; Mayes, Taryn L.; Ruberu, Maryse.

In: Pediatric Drugs, Vol. 7, No. 4, 2005, p. 203-217.

Research output: Contribution to journalArticle

Emslie, Graham J. ; Mayes, Taryn L. ; Ruberu, Maryse. / Continuation and maintenance therapy of early-onset major depressive disorder. In: Pediatric Drugs. 2005 ; Vol. 7, No. 4. pp. 203-217.
@article{b30068a4eecc4e74b894689b4033a7b4,
title = "Continuation and maintenance therapy of early-onset major depressive disorder",
abstract = "Child and adolescent depression is a serious and often episodic disorder with a high rate of recurrence equal to or surpassing that of adult depression. Symptoms of depression are similar in child, adolescent, and adult populations. The diagnostic criteria are the same, with the possible exception that children and adolescents are more likely to present with irritability without clear sadness. Despite the similarities between adult, adolescent, and child depression, results of studies of psychosocial and pharmacologic treatments in adult depression are not necessarily applicable to the pediatric population. The treatment of depression has been divided into three phases: acute (leading to clinical response and remission of symptoms); continuation (prevention of symptom relapse); and maintenance (prevention of new episodes or recurrences). According to research of acute treatment of child and adolescent depression with pharmacotherapy, selective serotonin reuptake inhibitors (SSRIs) are considered the first-line treatment. Recent controversies have caused some concern about the use of SSRIs in children and adolescents; however, SSRIs remain the initial pharmacologic treatment of choice. Acute treatment with non-specific psychotherapy is considered an essential component in the management of depression, but has not been shown to be equally effective as pharmacotherapy or specific psychotherapies by itself. There is increasing evidence that cognitive behavior therapy and interpersonal therapy are effective for the treatment of early-onset depression. Unfortunately, severe depression, comorbid diagnoses, family discord, and increased impairment may hinder the establishment of remission; these factors have been associated with treatment resistance. Once remission of depressive symptoms is established, continuation and maintenance treatment should be considered. Only one study of continuation treatment has been completed in child and adolescent depression; the results support the use of fluoxetine as a safe and effective treatment for reducing relapse. To date, no studies have been reported on maintenance treatment with specific therapies in child and adolescent depression, but trials in adults have demonstrated the importance of continued pharmacotherapy beyond the continuation phase of the illness. Although several factors are associated with response to treatment in children and adolescents with depression, including younger age, lower severity of depressive symptoms, higher family functioning, and fewer comorbid diagnoses, few studies have consistently demonstrated predictors of relapse and recurrence.",
author = "Emslie, {Graham J.} and Mayes, {Taryn L.} and Maryse Ruberu",
year = "2005",
doi = "10.2165/00148581-200507040-00001",
language = "English (US)",
volume = "7",
pages = "203--217",
journal = "Paediatric Drugs",
issn = "1174-5878",
publisher = "Adis International Ltd",
number = "4",

}

TY - JOUR

T1 - Continuation and maintenance therapy of early-onset major depressive disorder

AU - Emslie, Graham J.

AU - Mayes, Taryn L.

AU - Ruberu, Maryse

PY - 2005

Y1 - 2005

N2 - Child and adolescent depression is a serious and often episodic disorder with a high rate of recurrence equal to or surpassing that of adult depression. Symptoms of depression are similar in child, adolescent, and adult populations. The diagnostic criteria are the same, with the possible exception that children and adolescents are more likely to present with irritability without clear sadness. Despite the similarities between adult, adolescent, and child depression, results of studies of psychosocial and pharmacologic treatments in adult depression are not necessarily applicable to the pediatric population. The treatment of depression has been divided into three phases: acute (leading to clinical response and remission of symptoms); continuation (prevention of symptom relapse); and maintenance (prevention of new episodes or recurrences). According to research of acute treatment of child and adolescent depression with pharmacotherapy, selective serotonin reuptake inhibitors (SSRIs) are considered the first-line treatment. Recent controversies have caused some concern about the use of SSRIs in children and adolescents; however, SSRIs remain the initial pharmacologic treatment of choice. Acute treatment with non-specific psychotherapy is considered an essential component in the management of depression, but has not been shown to be equally effective as pharmacotherapy or specific psychotherapies by itself. There is increasing evidence that cognitive behavior therapy and interpersonal therapy are effective for the treatment of early-onset depression. Unfortunately, severe depression, comorbid diagnoses, family discord, and increased impairment may hinder the establishment of remission; these factors have been associated with treatment resistance. Once remission of depressive symptoms is established, continuation and maintenance treatment should be considered. Only one study of continuation treatment has been completed in child and adolescent depression; the results support the use of fluoxetine as a safe and effective treatment for reducing relapse. To date, no studies have been reported on maintenance treatment with specific therapies in child and adolescent depression, but trials in adults have demonstrated the importance of continued pharmacotherapy beyond the continuation phase of the illness. Although several factors are associated with response to treatment in children and adolescents with depression, including younger age, lower severity of depressive symptoms, higher family functioning, and fewer comorbid diagnoses, few studies have consistently demonstrated predictors of relapse and recurrence.

AB - Child and adolescent depression is a serious and often episodic disorder with a high rate of recurrence equal to or surpassing that of adult depression. Symptoms of depression are similar in child, adolescent, and adult populations. The diagnostic criteria are the same, with the possible exception that children and adolescents are more likely to present with irritability without clear sadness. Despite the similarities between adult, adolescent, and child depression, results of studies of psychosocial and pharmacologic treatments in adult depression are not necessarily applicable to the pediatric population. The treatment of depression has been divided into three phases: acute (leading to clinical response and remission of symptoms); continuation (prevention of symptom relapse); and maintenance (prevention of new episodes or recurrences). According to research of acute treatment of child and adolescent depression with pharmacotherapy, selective serotonin reuptake inhibitors (SSRIs) are considered the first-line treatment. Recent controversies have caused some concern about the use of SSRIs in children and adolescents; however, SSRIs remain the initial pharmacologic treatment of choice. Acute treatment with non-specific psychotherapy is considered an essential component in the management of depression, but has not been shown to be equally effective as pharmacotherapy or specific psychotherapies by itself. There is increasing evidence that cognitive behavior therapy and interpersonal therapy are effective for the treatment of early-onset depression. Unfortunately, severe depression, comorbid diagnoses, family discord, and increased impairment may hinder the establishment of remission; these factors have been associated with treatment resistance. Once remission of depressive symptoms is established, continuation and maintenance treatment should be considered. Only one study of continuation treatment has been completed in child and adolescent depression; the results support the use of fluoxetine as a safe and effective treatment for reducing relapse. To date, no studies have been reported on maintenance treatment with specific therapies in child and adolescent depression, but trials in adults have demonstrated the importance of continued pharmacotherapy beyond the continuation phase of the illness. Although several factors are associated with response to treatment in children and adolescents with depression, including younger age, lower severity of depressive symptoms, higher family functioning, and fewer comorbid diagnoses, few studies have consistently demonstrated predictors of relapse and recurrence.

UR - http://www.scopus.com/inward/record.url?scp=27744453342&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=27744453342&partnerID=8YFLogxK

U2 - 10.2165/00148581-200507040-00001

DO - 10.2165/00148581-200507040-00001

M3 - Article

C2 - 16117558

AN - SCOPUS:27744453342

VL - 7

SP - 203

EP - 217

JO - Paediatric Drugs

JF - Paediatric Drugs

SN - 1174-5878

IS - 4

ER -